In the single-agent bevacizumab group, median PFS was 10.8 versus 8.7 months in patients with WT and MT KRAS tumours, respectively (p = 0.0492; HR: 1.38; 95% CI, 1.00–1.89). Here, KRAS is linked to neoplasm.